Current Report Filing (8-k)
March 21 2018 - 1:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act
of 1934.
Date of Report: March 20, 2018
(Date of earliest event reported)
BioVie Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Nevada
|
|
333-190635
|
|
46-2510769
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
100 Cummings Center, Suite 247-C, Beverly, MA
|
|
01915
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(312) 283-5793
(Registrant’s telephone number,
including area code)
NanoAntibiotics, Inc.
(Former Name or Former Address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 4.01 Changes in Registrant’s Certifying Accountant.
On March 9, 2018, BioVie Inc. ("
BioVie
"
or “
Company
”) filed a Form 8-K pertaining to its change in accounting firms. In compliance with Item 304(a)(3)
of Regulation S-K, BioVie submits, as an attachment hereto, a letter from its former accounting firm, stating its agreement with
statements made by BioVie in that earlier filing. That letter was unavailable at the time BioVie made its March 9 Form 8-K filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:
March 21, 2018
|
|
|
|
BIOVIE INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jonathan Adams
|
|
|
|
|
|
|
|
Jonathan Adams
|
|
|
|
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|